The UK has conditionally approved Enhertu® (trastuzumab deruxtecan) as a monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer based on Phase II trial results.
List view / Grid view
Enhertu (trastuzumab deruxtecan)
Filter the results
The EMA's human medicines committee has released its results for the December meeting, suggesting which therapies should receive marketing authorisation.
A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.